Market Size of Japan Oral Anti-Diabetic Drug Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Market Size (2024) | USD 2.42 Billion |
Market Size (2029) | USD 3.02 Billion |
CAGR (2024 - 2029) | 4.60 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Japan Oral Anti-Diabetic Drug Market Analysis
The Japan Oral Anti-Diabetic Drug Market size is estimated at USD 2.42 billion in 2024, and is expected to reach USD 3.02 billion by 2029, growing at a CAGR of 4.60% during the forecast period (2024-2029).
Japanese victims of the COVID-19 pandemic were less numerous than those from other nations, which may be related to genetic variations, features of Japanese culture, and differences in the coagulation system between Japanese and Caucasians. The Osaka Prefectural Government categorized patients as mild, moderate, or severe and assigned them to various alternative accommodations in order to ease hospital overpopulation. Hospitals provide patient care in accordance with national government regulations. They focused on individuals with intermediate conditions or those with acceptable oxygen saturation values despite the presence of symptoms on computed tomography. Type 2 diabetes is linked to a sedentary lifestyle, which fosters the development of innate insulin resistance, in contrast to Type 1 diabetes, which is brought on by immune system dysfunction.
Japan's rising older population, who are more susceptible to disease, as well as an increase in obesity brought on by inactivity and irregular eating patterns, are regarded to be contributing factors to the country's rising diabetes incidence. As a result of being referred to a medical facility based on the findings of the metabolic syndrome examination, which was implemented in 2008 to avoid lifestyle-related disorders, more people have been diagnosed with the disease, which is another factor. With an aging population, diabetes cases are predicted to increase even more in Japan.
Globally, diabetes has become an epidemic; the IDF 2021 estimates that there are 11 million diabetics in Japan. Type 2 diabetes is linked to a sedentary lifestyle, which fosters the development of innate insulin resistance, in contrast to Type 1 diabetes, which is brought on by immune system dysfunction. Hence, Type 1 diabetes can be categorized as insulin-requiring diabetes, whereas Type 2 diabetes can be categorized as insulin-dependent diabetes. As one of the largest geriatric populations in the world, Japan is particularly susceptible to developing type 2 diabetes. With an aging population, diabetes is becoming more prevalent in Japan. Monitoring and controlling blood sugar levels are becoming more common in order to prevent harmful effects, including cardiovascular disease, kidney diseases, and other conditions.